FindTrial
Sign In

The role of platelet and thrombopoietin in chronic hepatitis B-related acute liver failure and its influence on liver regeneration

The role of platelet and thrombopoietin in chronic hepatitis B-related acute liver failure and its influence on liver regeneration

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100046728
Enrollment
Unknown
Registered
2021-05-27
Start date
2021-06-01
Completion date
Unknown
Last updated
2022-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver failure

Interventions

TPO group:injection of TPO
Control group:none

Sponsors

Tianjin Third Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-60 years, patients who meet the diagnostic criteria of HBV-ACLF; 2. Patients with platelet count lower than normal on admission.

Exclusion criteria

Exclusion criteria: 1. Combined with autoimmune hepatitis; 2. Patients with hepatitis C virus infection or HIV or other respiratory virus infections; 3. Complete liver malignant tumors; 4. Apply an immunosuppressive agent before treatment; 5. Infusion of platelets or application to increase platelet drugs during treatment; 6. Digestive hemorrhage during treatment.

Design outcomes

Primary

MeasureTime frame
liver function;—

Countries

China

Contacts

Public ContactLiang Jing

Tianjin Third Central Hospital

haoele77@sina.com+86 13163135596

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026